STOCK TITAN

Puma Biotechnology Inc - PBYI STOCK NEWS

Welcome to our dedicated news page for Puma Biotechnology (Ticker: PBYI), a resource for investors and traders seeking the latest updates and insights on Puma Biotechnology.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Puma Biotechnology's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Puma Biotechnology's position in the market.

Rhea-AI Summary
Puma Biotechnology announced the grant of an inducement restricted stock unit award to a new non-executive employee. The award covers 15,000 shares of Puma common stock and vests over a three-year period. It was granted under Puma's 2017 Employment Inducement Incentive Award Plan.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.2%
Tags
none
-
Rhea-AI Summary
Puma Biotechnology, Inc. (NASDAQ: PBYI) reported financial results for Q3 2023, with product revenue of $51.6 million, a decrease from $54.3 million in Q3 2022. Net income for Q3 2023 was $5.8 million, compared to a net loss of $0.4 million in Q3 2022. The company had cash, cash equivalents, and marketable securities of $85.0 million as of September 30, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.65%
Tags
-
Rhea-AI Summary
Puma Biotechnology to host conference call following release of Q3 2023 financial results
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.28%
Tags
conferences earnings
Rhea-AI Summary
Puma Biotechnology presents Phase I/II trial results of alisertib plus pembrolizumab for treatment of Rb-deficient head and neck squamous cell carcinoma at AACR-NCI-EORTC Conference.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Puma Biotechnology grants inducement restricted stock unit award to new non-executive employee
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.22%
Tags
none
-
Rhea-AI Summary
Puma Biotechnology receives Orphan Drug Designation from FDA for alisertib in small cell lung cancer, indicating progress in development
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.34%
Tags
Rhea-AI Summary
Puma Biotechnology to present at H.C. Wainwright Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.93%
Tags
conferences
-
Rhea-AI Summary
Puma Biotechnology has received FDA approval to proceed with the clinical development of alisertib monotherapy for the treatment of extensive stage small cell lung cancer. The Phase II trial will enroll up to 60 patients who have progressed after first-line platinum-based chemotherapy and immunotherapy. The primary endpoint of the trial will be objective response rate.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.81%
Tags
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.52%
Tags
Rhea-AI Summary
Puma Biotechnology, Inc. (NASDAQ: PBYI) to host conference call following the release of second quarter 2023 financial results. Access the call by dialing 1-877-709-8150 (domestic) or 1-201-689-8354 (international) and join the webcast on the Investors section of the Puma Biotechnology website. A replay will be available on the website for 90 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.31%
Tags
conferences earnings
Puma Biotechnology Inc

Nasdaq:PBYI

PBYI Rankings

PBYI Stock Data

254.05M
29.40M
15.12%
66.91%
6.83%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States
Los Angeles

About PBYI

we focus on in-licensing innovative drug candidates that are undergoing or have already completed initial clinical testing for the treatment of various forms of cancer and then seek to further develop these drug candidates for commercial use.